Preclinical [Alzheimer's Disease](/diseases/alzheimers-disease) represents the earliest stage of the Alzheimer's disease continuum, characterized by biomarker evidence of [amyloid-beta](/proteins/amyloid-beta) (Aβ) and/or [tau](/proteins/tau) pathology in the absence of detectable cognitive symptoms or functional decline. This stage can precede clinical symptoms by years to decades and represents the optimal window for disease-modifying interventions aimed at preventing or delaying downstream cognitive decline.
Overview and Conceptual Framework
Definition
The National Institute on Aging-Alzheimer's Association (NIA-AA) research framework defines preclinical AD as a biological construct based on biomarker evidence of AD pathology in individuals who are cognitively normal[@jack2018]:
Stage 1: Evidence of amyloid accumulation (positive amyloid PET or reduced CSF Aβ42/Aβ40)
Stage 2: Evidence of amyloid accumulation PLUS subtle cognitive decline
Stage 3: Evidence of amyloid accumulation, cognitive decline, AND subtle functional changes
This framework emphasizes that AD is a biological disease that begins long before clinical symptoms emerge, creating opportunities for early detection and intervention[@dubois2016].
Disease Timeline
The preclinical phase represents the longest portion of the AD continuum:
...
Preclinical Alzheimer's Disease
Preclinical [Alzheimer's Disease](/diseases/alzheimers-disease) represents the earliest stage of the Alzheimer's disease continuum, characterized by biomarker evidence of [amyloid-beta](/proteins/amyloid-beta) (Aβ) and/or [tau](/proteins/tau) pathology in the absence of detectable cognitive symptoms or functional decline. This stage can precede clinical symptoms by years to decades and represents the optimal window for disease-modifying interventions aimed at preventing or delaying downstream cognitive decline.
Overview and Conceptual Framework
Definition
The National Institute on Aging-Alzheimer's Association (NIA-AA) research framework defines preclinical AD as a biological construct based on biomarker evidence of AD pathology in individuals who are cognitively normal[@jack2018]:
Stage 1: Evidence of amyloid accumulation (positive amyloid PET or reduced CSF Aβ42/Aβ40)
Stage 2: Evidence of amyloid accumulation PLUS subtle cognitive decline
Stage 3: Evidence of amyloid accumulation, cognitive decline, AND subtle functional changes
This framework emphasizes that AD is a biological disease that begins long before clinical symptoms emerge, creating opportunities for early detection and intervention[@dubois2016].
Disease Timeline
The preclinical phase represents the longest portion of the AD continuum:
Amyloid accumulation: Begins 20-30 years before expected clinical symptoms
Tau pathology: Begins approximately 10-15 years before symptoms
Neurodegeneration: Begins 5-10 years before symptoms
Cognitive changes: Subtle changes detectable 3-5 years before MCI
Epidemiology
Prevalence
Amyloid-positive cognitively normal: Approximately 10-30% of individuals aged 50-70, increasing with age
Autosomal dominant AD: Nearly 100% develop preclinical changes by middle age
Sporadic AD risk: Approximately 20-40% of cognitively normal elderly are amyloid-positive
Risk Factors
Non-modifiable:
Age (strongest risk factor)
Genetics: [APOE](/proteins/apoe) ε4 allele (3-4x increased risk), family history
Sex (women slightly higher risk)
Potentially modifiable:
Cardiovascular risk factors
Education/cognitive reserve
Lifestyle factors
Sleep quality
Biomarkers and Detection
Amyloid Biomarkers
CSF Analysis
Aβ42/Aβ40 ratio: Reduced ratio reflects cortical amyloid deposition
Aβ42: Historically used, now largely replaced by ratio
Threshold: Ratio <0.1 typically indicates amyloid positivity
Amyloid PET Imaging
Radiotracers: Florbetapir (Amyvid), Florbetaben (Neuraceq), Pittsburgh compound B (PIB)
Visual read: Binary positive/negative assessment
Standardized uptake value ratio (SUVR): Quantitative measurement
Cortical binding: Predominantly in frontal, parietal, posterior cingulate regions
Tau Biomarkers
CSF Biomarkers
Phosphorylated tau (p-tau): Specific to AD tau pathology
p-tau181: Most widely used
[p-tau217](/biomarkers/p-tau-217): Emerging, may be more specific
p-tau231: Earlier marker
Total tau (t-tau): Marker of neuronal injury, less specific
Tau PET
Radiotracer: Flortaucipir (Tauvid)
Binding pattern: [Entorhinal cortex](/brain-regions/entorhinal-cortex), limbic regions, then isocortical
Clinical use: Currently approved for tau assessment
Neurodegeneration Biomarkers
MRI
Hippocampal atrophy: Sensitive to early AD changes
[Sperling RA, Aisen PS, Beckett LA, et al, Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21514248/)
[Jack CR Jr, Bennett DA, Blennow K, et al, NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29653606/)
[Dubois B, Hampel H, Feldman HH, et al, Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria (2016)](https://pubmed.ncbi.nlm.nih.gov/27012482/)
[Cummings J, Lee G, Ritter A, et al, Alzheimer's disease drug development pipeline: 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/36811460/)